{
    "clinical_study": {
        "@rank": "159894", 
        "acronym": "SMART-CHOICE", 
        "arm_group": [
            {
                "arm_group_label": "P2Y12 antagonist monotherapy", 
                "arm_group_type": "Experimental", 
                "description": "P2Y12 antagonist monotherapy after 3-month DAPT"
            }, 
            {
                "arm_group_label": "Aspirin + P2Y12 antagonist", 
                "arm_group_type": "Experimental", 
                "description": "Aspirin + P2Y12 antagonist after 3-month DAPT"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the efficacy and safety of clopidogrel monotherapy versus aspirin plus P2Y12\n      antagonist following 3-month of DAPT in patients undergoing PCI with DES."
        }, 
        "brief_title": "Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES", 
        "completion_date": {
            "#text": "February 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "This trial is a prospective, randomized, multi-center, open label, noninferiority trial.\n      Patients undergoing PCI with DES will be eligible. After successful PCI with DES, all\n      eligible patients will be randomized either to clopidogrel monotherapy or to aspirin plus\n      P2Y12 antagonist following 3-month of DAPT."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject must be at least 20 years of age.\n\n          -  Subject is able to verbally confirm understandings of risks, benefits and treatment\n             alternatives and he/she or his/her legally authorized representative provides written\n             informed consent prior to any study related procedure.\n\n          -  Patients undergoing successful PCI\n\n        Exclusion Criteria:\n\n          -  Hemodynamic instability or cardiogenic shock\n\n          -  Active bleeding\n\n          -  Known hypersensitivity or contraindication to study medications\n\n          -  Female of childbearing potential, unless a recent pregnancy test is negative, who\n             possibly plan to become pregnant any time after enrollment into this study\n\n          -  Non-cardiac co-morbid conditions are present with life expectancy <2 year or that may\n             result in protocol non-compliance (per site investigator's medical judgment).\n\n          -  Angiographic exclusion criteria\n\n          -  Bifurcation lesions requiring side branch stenting\n\n          -  Lesions treated with 3 or more overlapped stents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079194", 
            "org_study_id": "SMC 2014-01-161"
        }, 
        "intervention": [
            {
                "arm_group_label": "P2Y12 antagonist monotherapy", 
                "intervention_name": "P2Y12 antagonist monotherapy", 
                "intervention_type": "Drug", 
                "other_name": "P2Y12 antagonist monotherapy"
            }, 
            {
                "arm_group_label": "Aspirin + P2Y12 antagonist", 
                "intervention_name": "aspirin plus P2Y12 antagonist", 
                "intervention_type": "Drug", 
                "other_name": "aspirin plus P2Y12 antagonist"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aspirin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Drug-eluting stents", 
            "aspirin", 
            "P2Y12 antagonist monotherapy"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "hc.gwon@samsung.com", 
                "last_name": "Hyeon-Cheol Gwon, Professor", 
                "phone": "82234103419"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "135-710"
                }, 
                "name": "Cardiac and Vascular Center; Samsung Medical Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison Between P2Y12 Antagonist MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary Drug-Eluting Stents", 
        "overall_contact": {
            "email": "hcgwon@skku.edu", 
            "last_name": "Hyeon-Cheol Gwon, MD,PhD", 
            "phone": "82-2-3410-3418"
        }, 
        "overall_contact_backup": {
            "email": "youngbin.song@gmail.com", 
            "last_name": "Young Bin Song, MD", 
            "phone": "82-2-3410-3419"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Hyeon-Cheol Gwon, MD,PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "over 3-12 months after the index procedure", 
            "measure": "A composite of death, myocardial infarction, cerebrovascular events, or BARC bleeding (grade II or higher)", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079194"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Hyeon-Cheol Gwon", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "All cause Death", 
                "safety_issue": "Yes", 
                "time_frame": "1 years"
            }, 
            {
                "measure": "cardiac death", 
                "safety_issue": "Yes", 
                "time_frame": "1 years"
            }, 
            {
                "measure": "Myocardial infarction (MI)", 
                "safety_issue": "Yes", 
                "time_frame": "1 years"
            }, 
            {
                "measure": "Cerebrovascular accident (CVA)", 
                "safety_issue": "Yes", 
                "time_frame": "1 years"
            }, 
            {
                "measure": "Target lesion revascularization (TLR)", 
                "safety_issue": "Yes", 
                "time_frame": "1 years"
            }, 
            {
                "measure": "Target vessel revascularization (TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "1 years"
            }, 
            {
                "measure": "Any revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "1 years"
            }, 
            {
                "measure": "Stent thrombosis: definite or probable stent thrombosis by ARC definition", 
                "safety_issue": "Yes", 
                "time_frame": "1 years"
            }, 
            {
                "measure": "BARC bleeding \u22652", 
                "safety_issue": "Yes", 
                "time_frame": "1 years"
            }, 
            {
                "measure": "BARC bleeding \u22653", 
                "safety_issue": "Yes", 
                "time_frame": "1 years"
            }, 
            {
                "measure": "Major adverse cardiocerebral event (MACCE): death, MI, CVA, or any revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "1 years"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}